NEW HAVEN, Conn., Oct. 20 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.
("Rib-X" or the "Company"), a development-stage company focused on the
discovery, development and commercialization of novel antibiotics for the
treatment of antibiotic-resistant infections, today announced that it will
present a poster entitled "A Phase 2 Study Comparing Two Doses of Radezolid
to Linezolid in Adults with Uncomplicated Skin and Skin Structure
Infections (uSSSI)" at the 2008 ICAAC/IDSA Joint Meeting in Washington,
D.C. Details on the presentation are as follows:
Poster Session: New Treatment Options in Skin and Soft
Poster Title: A Phase 2 Study Comparing Two Doses of
Radezolid to Linezolid in Adults with
Uncomplicated Skin and Skin Structure
Date: Sunday, October 26, 2008
Time: 12:15pm ET - 1:15pm ET
Location: Hall C
"We are extremely proud to have been selected to present at the leading global antimicrobials conference," said Susan Froshauer, PhD, President and Chief Executive Officer, Rib-X Pharmaceuticals. "These data result from one of two proof-of-concept phase 2 trials with radezolid, a compound which derives from the Rib-X proprietary drug discovery approach. It is an honor to have our work recognized by the ICAAC/IDSA joint meeting organizers."
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug
discovery and development company focused on the structure-based design of
new classes of antibiotics. The Company's underlying drug discovery engine
capitalizes on its proprietary high-resolution crystal structure of the
ribosome, which performs an essential role in protein synthesis. Many
known, commercially valuable antibiotics exert their effec
|SOURCE Rib-X Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved